Cochrane COVID-19 Studienregister
Studienbericht
NCT05074368Erstmals veröffentlicht: 2021 Okt 12Letzte Aktualisierung: 2021 Okt 12

Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination

  1. Studientyp
  2. Interventional
  1. Studienziel
  2. Prevention
  1. Studiendesign
  2. Parallel/Crossover
  1. Interventionszuordnung
  2. Non-randomised
Referenzdatensätze

Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination

National Taiwan University Hospital
Erstmals veröffentlicht (first received 2021 October 12)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT05074368)
Eintrag in Studienregister
Keine Ergebnisse
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation. Healthy volunteers will be enrolled and divided into five groups. The first group is the subjects who received ChAdOx1- nCov-19 vaccine with 8 weeks apart; the second group is the SARS-CoV-2 messenger RNA-1273 vaccine after the first dose of ChAdOx1-nCov-19 vaccination with 8 weeks apart; the third group is the first dose of ChAdOx1-nCov-19 vaccine and the SARS-CoV-2 messenger RNA-1273 vaccine with 4 weeks apart; the fourth group is the SARS-CoV-2 messenger RNA-1273 vaccination with 4 weeks apart; the fifth group is the first dose of ChAdOx1-nCov-19 vaccine and the SARS-CoV-2 messenger RNA-1273 vaccine with 12 weeks apart. There will be 100 volunteers in each group. Antibody test on the day before and the 14th, 28th day and 12th week after the second dose of vaccination, including 100 subjects in each group for SARS-CoV-2 ELISA antibody titer and 50 people in each group for SARS-CoV-2 neutralizing antibody titer. Adverse reactions at the first day, the 14th day, the 28th day, and the 12th week. The research team follow up each volunteer at the 6th month